A2780 Cell Line

A well-characeterised human ovarian cancer cell line widely used to study cisplatin resistance, therapeutic response, and ovarian cancer biology. Save 30% on this cell line this summer. Use code SUM26CELL at checkout.

Contributors

Inventor Institute
Dr Stuart Aaronson National Cancer Institute
SKU: 152706
Product description: A2780 is a widely used human ovarian cancer cell line that provides a cisplatin-sensitive reference model for studies of drug response, chemotherapy sensitivity and ovarian cancer biology. It is particularly useful as the parental comparator for resistant derivatives, including A2780cis, supporting paired analysis of treatment sensitivity, acquired resistance and drug-response mechanisms.
Alternate name: A-2780 Cells; A2780 ovarian cancer cell line
Conditional: Yes
Production details: Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 3-6×10,000cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C.
Additional notes: This epithelial cell line grows as a monolayer, in suspension in spinner cultures, and is tumourigenic in immune deficient mice. A2780 displays cisplatin-sensitivity. Our collection also features seven A2780 derivatives, including two drug resistant cell line variants: a cisplatin resistant cell line A2780 cis (catalogue no. 152708) and the adriamycin resistant cell line – A2780 ADR (catalogue no. 152707). Published uses of this line include: (1) Investigating the role of ovarian tumour neovascularisation (Abdulkhalek et al. 2014) (2) Resistance to chemotherapeutic drugs (Januchowski et al. 2014) (3) Demonstrating significance of therapeutic targets in ovarian cancer (Pfankuchen et al. 2015). STR-PCR Data: Amelogenin: X CSF1PO: 10,11 D13S317: 12,13 D16S539: 11,13 D5S818: 11,12 D7S820: 10 THO1: 6 TPOX: 8,10 vWA: 15,16
Cellosaurus ID: CVCL_0134
Disease: Cancer
Cat. #: 152706
Unit size: 1×10^6 cells / vial
Cancer types: Ovarian cancer
Research Fields: Cancer; Drug development
Organism: Human
Tissue: Ovary
Model: Tumour line
Growth properties: Adherent
Cancer Types In Detail: Ovarian
Format: Frozen
Shipping conditions: Dry ice
Growth medium: RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
References:

Nusinow et al. 2020. Cell. 180(2):387-402.e16. PMID: 31978347.

Ghandi et al. 2019. Nature. 569(7757):503-508. PMID: 31068700.

Dutil et al. 2019. Cancer Res. 79(7):1263-1273. PMID: 30894373.

Zhao et al. 2017. Clin Proteomics. 14:20. PMID: 28546799.

Medrano et al. 2017. Cell Rep. 18(10):2343-2358. PMID: 28273451.

Pfankuchen et al. 2015. Biochem Pharmacol. 97(2):147-57. PMID: 26239805.

Abdulkhalek et al. 2014. Clin Transl Med. 3(1):28. PMID: 26932374.

Januchowski et al. 2014. Biomed Res Int. 2014:365867. PMID: 24804215

Parker et al. 1991. J Clin Invest. 87(3):772-777. PMID: 1999494.

Images

View Gallery
A2780 Cell Line. 48 hours post plating. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC).

Citations And Reviews

Related Tools for Cell lines

Cat. # Tool Name
151576 MEF RAF1 KO Cell Line Key Info View Tool
151479 HCT 116 p300 KO [D10] Cell Line Key Info View Tool
151629 MEF Raf1 FF/FF KI Cell Line Key Info View Tool
151630 PDVC57B Cell Line Key Info View Tool
151655 FLYA-13 Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.